The in-vivo dynamics of Plasmodium falciparum HRP2: implications for the use of rapid diagnostic tests in malaria elimination

L Marquart; L Webb; P O’Rourke; ML Gatton; MS Hsiang; M Kalnoky; IK Jang; H Ntuku; DR Mumbengegwi; GJ Domingo; JS McCarthy; S Britton

Journal article

The in-vivo dynamics of Plasmodium falciparum HRP2: implications for the use of rapid diagnostic tests in malaria elimination

L Marquart, L Webb, P O’Rourke, ML Gatton, MS Hsiang, M Kalnoky, IK Jang, H Ntuku, DR Mumbengegwi, GJ Domingo, JS McCarthy, S Britton

Malaria Journal | BMC | Published : 2022

DOI: 10.1186/s12936-022-04245-z

Download PDF

Abstract

Background: Rapid diagnostic tests (RDTs) that rely on the detection of Plasmodium falciparum histidine-rich protein 2 (PfHRP2) have become key tools for diagnosing P. falciparum infection. The utility of RDTs can be limited by PfHRP2 persistence, however it can be a potential benefit in low transmission settings where detection of persistent PfHRP2 using newer ultra-sensitive PfHRP2 based RDTs can serve as a surveillance tool to identify recent exposure. Better understanding of the dynamics of PfHRP2 over the course of a malaria infection can inform optimal use of RDTs. Methods: A previously published mathematical model was refined to mimic the production and decay of PfHRP2 during a malari..

View full abstract

University of Melbourne Researchers

James McCarthy Author

Related Projects (2)

Translational Studies in Malaria

The growing momentum towards elimination of malaria and the need to control of drug-resistant parasites means that new drugs and vaccines ar..

Tropical diseases: Translating discoveries into better health

Major progress being made in control of many infectious diseases occurring in tropical areas, including malaria worms and the bacteria that ..

Grants

Awarded by University of Namibia

Funding Acknowledgements

This work was supported, in whole or in part, by the Bill & Melinda Gates Foundation (Grant Numbers: 347 OPP1135840 and A128488). Under the grant conditions of the Foundation, a Creative Commons Attribution 4.0 Generic License has already been assigned to the Author Accepted Manuscript version that might arise from this submission. This work for the IBSM studies was financially supported by Medicines for Malaria Venture through a Wellcome Trust grant (reference number 095909/Z/11/Z), a grant by the Global Health Innovation and Technology Fund (GHIT) (Grant No. G2014-108), and by funding from the Bill and Melinda Gates Foundation. Antigen quantification work conducted at PATH was supported by an award to PATH in whole by the Bill & Melinda Gates Foundation [Grant Number 347 OPP1135840]. The Namibia Cohort Study was funded by the Bill and Melinda Gates Foundation (A128488) and University of Texas Southwestern Department of Pediatrics Horchow Family Fund (5300375400). JSM was supported by an Australian government National Health and Medical Research Council (NHMRC) Practitioner Fellowship (APP1135955) and supported by an NHMRC Program Grant (1132975).